Core Viewpoint - Tonghua Golden Horse plans to invest 70 million yuan to establish a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd, to enhance its strategic focus on innovation-driven development in the pharmaceutical industry [1] Group 1: Investment and Strategic Development - The investment of 70 million yuan will be sourced from the company's own or raised funds [1] - The establishment of the subsidiary aligns with the company's strategy to transform into an innovation-driven modern pharmaceutical enterprise [1] - The move aims to strengthen the company's capabilities in mergers and acquisitions within the innovative drug sector, thereby enhancing its core competitiveness [1] Group 2: Long-term Sustainability - The initiative is intended to inject new momentum into the company's long-term sustainable development [1]

Core Viewpoint - Tonghua Golden Horse (000766.SZ) plans to invest 70 million yuan to establish a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd, to support its strategic shift towards becoming an innovation-driven modern pharmaceutical enterprise [1] Group 1: Investment and Strategic Development - The investment of 70 million yuan will be sourced from the company's own or raised funds [1] - The establishment of the subsidiary is aimed at enhancing the company's capabilities in mergers and acquisitions within the innovative pharmaceutical industry [1] - This move is part of the company's long-term strategy to boost its core competitiveness and ensure sustainable development [1]

Core Viewpoint - Tonghua Golden Horse (000766.SZ) plans to invest 70 million yuan to establish a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd, to support its strategic shift towards becoming an innovation-driven modern pharmaceutical enterprise [1] Group 1: Investment and Strategic Development - The investment of 70 million yuan will be sourced from the company's own funds or raised funds [1] - The establishment of the subsidiary is aligned with the company's strategy to enhance its capabilities in the innovative drug industry through mergers and acquisitions [1] - This move aims to strengthen the company's core competitiveness and inject new momentum into its long-term sustainable development [1]

Core Viewpoint - Tonghua Golden Horse announced the establishment of a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd., with an investment of 70 million yuan to enhance its strategic transformation in the innovative pharmaceutical industry [1] Group 1: Company Actions - The company will hold its 11th board meeting on November 6, 2025, to approve the investment proposal [1] - The investment will be funded through the company's own or raised funds, and the company will hold 100% of the new subsidiary [1] - The investment decision falls within the board's approval authority and does not constitute a related party transaction or a major asset restructuring [1] Group 2: Strategic Intent - The purpose of this investment is to conduct mergers and acquisitions in the innovative pharmaceutical sector as part of the company's transformation strategy [1] - The company acknowledges that the investment may be influenced by industry policies but believes it will help optimize its industrial layout [1]